Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Alana on +44 1494 818 040 or alana@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Alana McKenna
Senior Account Manager
alana@zenopa.com
+44 1494 818 040

Testimonials
Even though I never actually met anyone from Zenopa, all of the support they gave me over the phone or by email which was all I needed to help me on my way.
Claire, 2014

Ark Therapeutics achieves milestone in PsiOxus partnership

5 January 2012 00:00 in Medical Company Product News


Ark Therapeutics has successfully met the first milestone in its manufacturing alliance with PsiOxus Therapeutics, as outlined in September 2011.

The company has been able to produce the ColoAd1 oncoloytic adenoviral product at its facility in Kuopio, Finland in a timely manner, allowing PsiOxus to initiate final pre-clinical toxicology studies of the compound.

Ark utilises its proprietary suspension-based single use process ATOSUS to achieve the necessary product quality and demonstrate the capability to exceed target process yields, which will aid its partner's plans to commence phase I testing in 2012.

This will help to bring a potentially promising new therapy option for colorectal cancer one step closer to market readiness.

Martyn Williams, chief executive officer of Ark, added: "This further validation for Ark's ATOSUS process as a platform for adenoviral manufacture is very helpful as we continue discussions with other potential partners."

This comes after Ark recently agreed to provide manufacturing services for the University of Glasgow in order to support a gene therapy programme.ADNFCR-8000103-ID-801256313-ADNFCR

Other news stories from 05/01/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd